DEF: LENZ Therapeutics Sets Date for 2025 Annual Stockholders Meeting

LENZ Therapeutics announces its annual meeting of stockholders to be held virtually on June 10, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Summary

• LENZ Therapeutics will hold its annual meeting of stockholders on June 10, 2025, at 10:00 a.m., Pacific Time, conducted virtually.
• Stockholders of record as of April 14, 2025, are entitled to vote at the meeting.
• The meeting will include the election of two Class III directors to serve until the 2027 annual meeting and two Class I directors to serve until the 2028 annual meeting.
• Stockholders will also vote to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• Proxy materials were first sent to stockholders on or about April 28, 2025, and are accessible online at www.proxydocs.com/LENZ.
• The board of directors recommends voting for the election of the director nominees and for the ratification of Ernst & Young LLP's appointment.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting factual information in a neutral tone. The sentiment is moderately positive due to the routine nature of the meeting and the board's recommendations.

Positives

• The company is providing a virtual meeting option for stockholders.
• The board is recommending a clear course of action on the proposals.
• Stockholders have multiple options for voting: Internet, telephone, or mail.

Future Outlook

The document outlines the business to be conducted at the annual meeting, focusing on governance and auditing matters for the upcoming fiscal year.

Management Comments

• On behalf of our Board of Directors, we would like to express our appreciation for your continued support of and interest in LENZ.
• Your vote is important.

Industry Context

This announcement is a routine part of corporate governance, ensuring stockholders have a voice in the company's direction and oversight.

Comparison to Industry Standards

• The virtual meeting format aligns with current trends in corporate governance, offering accessibility to a wider range of stockholders, similar to companies like Zoom and Teladoc.
• The staggered board structure is a common practice among publicly traded companies, such as Amgen and Gilead Sciences, to ensure continuity and experience on the board.
• The process of appointing and ratifying an independent accounting firm is standard practice, mirroring the processes at companies like Apple and Microsoft.

Management Changes

Related Party Transactions

• Dr. Porteus, a director of Graphite prior to the closing of the Merger and stockholder of Graphite, is the founder and chief executive officer of Kamau.
• Maro was formed by Samsara BioCapital and funds affiliated with Versant Ventures, both of which were greater than 5% stockholders of Graphite.
• Zach Scheiner, a member of the LENZ board of directors, is an affiliate of RA Capital.
• Chris Dimitropoulos, a member of LENZ OpCos board of directors until immediately prior to the effective time of the Merger, is an affiliate of Alpha Wave Ventures II, LP.
• Stefan Larson, a member of LENZ OpCos board of directors until immediately prior to the effective time of the Merger, is a partner at Sectoral Asset Management Inc.
• James McCollum, a member of the LENZ board of directors, is the trustee of the McCollum Living Trust.
• Clare Ozawa, a member of the LENZ OpCo board of directors until immediately prior to the effective time of the Merger, is an affiliate of Versant Ventures.

Stakeholder Impact

• Stockholders have the opportunity to vote on key company matters.
• The election of directors and ratification of the accounting firm directly impact corporate governance and financial oversight.

Next Steps

• Stockholders are urged to vote on the proposals.
• The company will file a Form 8-K to disclose the voting results after the annual meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Director Election, Ernst & Young, Accounting Firm, LENZ Therapeutics